Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA444662
Max Phase: Preclinical
Molecular Formula: C34H36N2O10S
Molecular Weight: 664.73
Molecule Type: Small molecule
Associated Items:
ID: ALA444662
Max Phase: Preclinical
Molecular Formula: C34H36N2O10S
Molecular Weight: 664.73
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(N[C@H]1[C@@H](O)[C@@H](CO)O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@H](NC(=O)c3ccc4ccccc4c3)[C@H]2O)[C@@H]1O)c1ccc2ccccc2c1
Standard InChI: InChI=1S/C34H36N2O10S/c37-15-23-27(39)25(35-31(43)21-11-9-17-5-1-3-7-19(17)13-21)29(41)33(45-23)47-34-30(42)26(28(40)24(16-38)46-34)36-32(44)22-12-10-18-6-2-4-8-20(18)14-22/h1-14,23-30,33-34,37-42H,15-16H2,(H,35,43)(H,36,44)/t23-,24-,25+,26+,27+,28+,29-,30-,33+,34+/m1/s1
Standard InChI Key: GQWSITVOKHOLLL-SCODVAETSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 664.73 | Molecular Weight (Monoisotopic): 664.2091 | AlogP: 0.50 | #Rotatable Bonds: 8 |
Polar Surface Area: 198.04 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 8 |
#RO5 Violations: 3 | HBA (Lipinski): 12 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.65 | CX Basic pKa: | CX LogP: 0.73 | CX LogD: 0.73 |
Aromatic Rings: 4 | Heavy Atoms: 47 | QED Weighted: 0.13 | Np Likeness Score: 0.13 |
1. Delaine T, Cumpstey I, Ingrassia L, Le Mercier M, Okechukwu P, Leffler H, Kiss R, Nilsson UJ.. (2008) Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells., 51 (24): [PMID:19053747] [10.1021/jm801077j] |
2. Rajput VK, MacKinnon A, Mandal S, Collins P, Blanchard H, Leffler H, Sethi T, Schambye H, Mukhopadhyay B, Nilsson UJ.. (2016) A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model., 59 (17): [PMID:27500311] [10.1021/acs.jmedchem.6b00957] |
Source(1):